Phase 2 Trial Tests High-Induction Risankizumab in Plaque Psoriasis
A randomized phase 2 trial in Nature tests high-induction dosing of risankizumab in moderate-to-severe plaque psoriasis, probing whether front-loaded dosing speeds clearance.
Topic
Risankizumab
Topic
Risankizumab
Risankizumab Tops Ustekinumab on Complete Clearance in Pediatric Psoriasis
In phase 3 OptIMMize-1 data published in the British Journal of Dermatology, risankizumab matched ustekinumab on most endpoints a…
High-Dose Risankizumab Shows Fast, Durable Psoriasis Response
Medscape reports high-dose risankizumab delivered rapid psoriasis response, with a subset of patients maintaining clearance over…
Risankizumab Clears Persistent Facial Plaque Psoriasis in Case Report
A Cureus case report documents complete clearance of persistent facial plaque psoriasis with risankizumab after prior systemic th…